[sim00]

Hi all,

Just now, I read back this interesting news, appeared for the first time in September 2010, special thanks to Ronhutton:

http://neurotalk.psychcentral.com/sh...d.php?t=132790

Few months ago, August 2012, again:

http://siberiantimes.com/science/cas...each-patients/

The article said that in two years (2010 -> 2012), approximately, Russian scientists will begin testing on humans. It seems that everything is ready (they also registered copyright), but lack the funds to continue. However, I have found in internet, a document which talks about this mysterious compound (it doesn't a cure for PD, but remove symptoms almost at all, without developing side effects). The document is written in Russian, of course, but with the help of some online traslator, you can figure out something:

https://www.dropbox.com/s/55iqxuowbw4xso6/ardashov.pdf

We hope that they will do it quickly.

[ashleyk]

This, it appears, is the research paper from 2011. 1R,2R,6S seems like a common compound (meaning the drug companies are not interested).
Any bio-chemists up on looking at this?

http://en.wikipedia.org/wiki/Carveol
An alpha-trans-dihydroxy derivative ((1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol) possesses potent antiparkinsonian activity in animal models.[3]

Volcho Konstantin: http://lib.bioinfo.pl/auid:18047424

http://pubs.acs.org/doi/full/10.1021/jm2001579#
Our study demonstrates that (1R,2R,6S)-1 displays a potent antiparkinsonian activity in vivo on models with MPTP in mice and rats and is not inferior to the reference agent (levodopa). Compound (1R,2R,6S)-1 clearly improves the markers of the locomotor and exploratory activities, thus removing the signs of the parkinsonian syndrome induced by neurotoxin injection. The described activity is proved by a number of tests with varying duration of toxin and agent administration (1–30 days).
Compound (1R,2R,6S)-1 almost completely prevents the development of catalepsy caused by haloperidol, which is demonstrated by a notable decrease in the catalepsy duration in animals, the duration of haloperidol time course, and the percent of cataleptic animals.
We synthesized all eight stereoisomers of compound 1 from the available monoterpenoids (+)- and (−)-α-pinenes and (+)- and (−)-carvones for the first time. According to our observations, the absolute configuration of compound 1 greatly influences its antiparkinsonian activity in the test with MPTP, from nearly full removal to a sharp increase in the symptoms of the parkinsonian syndrome.